In Indian patients with acute coronary syndrome (ACS) or ST‑segment‑elevation myocardial infarction (STEMI), LDL cholesterol is often not elevated while triglycerides or remnant cholesterol are high and HDL cholesterol is low; how does this reconcile with LDL being the primary cause of atherosclerotic cardiovascular disease, and are atherosclerosis progression and myocardial infarction risk separate processes?

LDL Remains the Primary Causal Factor for ASCVD, But Remnant Cholesterol and Triglyceride-Rich Lipoproteins Are Equally Atherogenic Per Unit of Cholesterol

The apparent paradox in Indian ACS/STEMI patients—where LDL-C is often not elevated but triglycerides and remnant cholesterol (RC) are high—does not contradict LDL's causative role; rather, it demonstrates that cholesterol in triglyceride-rich lipoproteins (remnant cholesterol) is equally atherogenic to LDL cholesterol on a per-milligram basis, and both drive atherosclerosis progression and acute events through the same mechanism: cholesterol deposition in arterial walls.

Understanding the Lipid Paradox in South Asian Populations

The lipid profile you describe is characteristic of South Asians and is well-documented in guidelines 1. South Asians typically present with:

• Hypertriglyceridemia (often >150-200 mg/dL)
• Low HDL-C (<40 mg/dL in men, <50 mg/dL in women)
• Elevated remnant cholesterol (calculated as total cholesterol minus LDL-C minus HDL-C)
• Small, dense LDL particles despite "normal" LDL-C levels
• Elevated lipoprotein(a) in many cases

This pattern, termed "atherogenic dyslipidemia," is particularly prevalent in Indians and is associated with metabolic syndrome, insulin resistance, and visceral adiposity 1, 2.

Reconciling the Evidence: Why This Doesn't Contradict LDL Causality

1. Remnant Cholesterol Is Equally Atherogenic to LDL Cholesterol

The critical insight from recent research is that remnant cholesterol causes ASCVD through the same mechanism as LDL cholesterol—both deposit cholesterol in arterial walls 3, 4. Epidemiologic and genetic studies demonstrate that lowering remnant cholesterol and LDL cholesterol reduce ASCVD risk by similar magnitudes per 1 mmol/L (39 mg/dL) reduction in non-HDL cholesterol 4.

Remnant cholesterol includes cholesterol in:

• VLDL (very low-density lipoprotein)
• Intermediate-density lipoprotein
• Chylomicron remnants (postprandially)

These particles are directly atherogenic—they penetrate the arterial wall, become trapped, and drive plaque formation 3. Unlike triglycerides themselves (which don't accumulate in plaques), the cholesterol content of triglyceride-rich lipoproteins is the culprit 3.

2. Non-HDL Cholesterol Is the Better Target

Current guidelines now emphasize non-HDL cholesterol (which equals LDL-C + remnant cholesterol) as the primary target rather than LDL-C alone 5, 6. This is because:

• Non-HDL-C captures all atherogenic cholesterol (LDL + remnant cholesterol)
• It better predicts risk in patients with elevated triglycerides
• It's calculated simply: Total cholesterol - HDL-C

For post-ACS patients, the target is non-HDL-C <130 mg/dL (ideally substantially lower, <100 mg/dL) when triglycerides are ≥200 mg/dL 7, 8.

3. Small Dense LDL Particles Are More Atherogenic

Even when LDL-C levels appear "normal," South Asians often have qualitatively abnormal LDL characterized by smaller, denser particles 1. These particles:

• Penetrate the arterial wall more easily
• Are more susceptible to oxidation
• Are more atherogenic per particle

Recent evidence shows small dense LDL-C is independently associated with rapid progression of non-culprit coronary lesions and cardiovascular events in ACS patients 9. An on-treatment sd-LDL-C ≥20.9 mg/dL predicts adverse outcomes 9.

4. Remnant Cholesterol Predicts Mortality in STEMI

A 2024 study of 6,602 STEMI patients found that discordantly high remnant cholesterol (when RC is elevated despite normal LDL-C) was independently associated with 55% increased all-cause mortality and 47% increased cardiovascular death compared to discordantly low RC 10. This demonstrates that RC drives outcomes beyond LDL-C in the acute MI setting.

Atherosclerosis Progression vs. Acute MI Risk: Same Process, Different Timescales

Atherosclerosis progression and MI risk are NOT separate processes—they are the same continuum:

1. Chronic Phase (Atherosclerosis Progression):

   • Both LDL-C and remnant cholesterol drive gradual plaque accumulation
   • Elevated triglycerides (marker of high RC) correlate with plaque burden 11
   • TC/HDL ratio, LDL/HDL ratio, and ApoB levels correlate with Gensini scores (plaque burden) 11

2. Acute Phase (Plaque Rupture/MI):

   • Inflammatory processes destabilize plaques
   • Remnant cholesterol particles are particularly pro-inflammatory 3
   • Atherogenic dyslipidemia (high TG, low HDL) is associated with insulin resistance and systemic inflammation, which promote plaque instability 2

The same atherogenic lipoproteins that build plaques also make them vulnerable to rupture. The metabolic milieu in South Asians (insulin resistance, inflammation, visceral adiposity) accelerates both processes 1.

Clinical Implications for Indian ACS/STEMI Patients

Immediate Post-ACS Management

All ACS/STEMI patients should receive intensive lipid-lowering therapy at discharge, regardless of baseline LDL-C 12, 13, 14:

1. Start high-intensity statin immediately (atorvastatin 80 mg or rosuvastatin 40 mg) 13, 14

   • Even if LDL-C <100 mg/dL at baseline 15, 14
   • Measure lipids within 24 hours of admission to guide therapy 7

2. Target LDL-C <55 mg/dL (<1.4 mmol/L) for very high-risk patients (which includes all recent ACS) 12

   • Alternative target: ≥50% reduction from baseline 12

3. If triglycerides ≥150 mg/dL or HDL-C <40 mg/dL:

   • Emphasize weight management and physical activity 7
   • Target non-HDL-C substantially <130 mg/dL (ideally <100 mg/dL) 7, 8

4. If triglycerides 200-499 mg/dL after LDL-lowering:

   • Consider adding fibrate or niacin 7, 8
   • For patients with persistent hypertriglyceridemia (≥135-175 mg/dL) on statin: Consider icosapent ethyl (IPE) 4g daily, which reduced ASCVD events by 25% in REDUCE-IT 5

5. If LDL-C remains ≥55 mg/dL after 4-6 weeks on high-intensity statin:

   • Add ezetimibe 10 mg 12, 13
   • If still not at goal after another 4-6 weeks, add PCSK9 inhibitor 12

Special Considerations for South Asian/Indian Patients

For patients with diabetes or metabolic syndrome (common in this population):

• Consider pitavastatin with ezetimibe as initial therapy, which reduces new-onset diabetes risk 12
• Alternatively, use rosuvastatin 20 mg or atorvastatin 40 mg (lower than maximum doses) plus ezetimibe to balance efficacy with diabetes risk 12
• Bempedoic acid can be added if available—it lowers both LDL-C and glucose 12

The Bottom Line: A Unified Atherogenic Cholesterol Hypothesis

LDL cholesterol is not the ONLY primary causative factor—it's more accurate to say that ALL apoB-containing lipoproteins (LDL + remnant cholesterol) cause ASCVD through cholesterol deposition. The hypothesis should be reframed:

• "Atherogenic cholesterol" (non-HDL-C) = LDL-C + remnant cholesterol
• Both contribute equally per unit of cholesterol
• In South Asians, the relative contribution from remnant cholesterol is higher due to metabolic factors
• Triglycerides are a marker, not the cause—the cholesterol within triglyceride-rich lipoproteins is the culprit 3

The "LDL hypothesis" remains valid but incomplete. Modern guidelines recognize this by shifting focus to non-HDL-C and apoB (which measures all atherogenic particles) 6, 4. In Indian ACS patients, aggressive reduction of ALL atherogenic cholesterol—not just LDL-C—is essential for secondary prevention 12, 16.

Key Pitfall to Avoid

Do not withhold or delay intensive statin therapy in ACS patients with "normal" LDL-C. The evidence is unequivocal that statins reduce events post-ACS regardless of baseline LDL-C 15, 14. The benefit comes from:

• Lowering all atherogenic cholesterol (LDL + remnant)
• Pleiotropic anti-inflammatory effects
• Plaque stabilization

Start high-intensity statin at discharge in ALL ACS patients 12, 13, 16. Address the atherogenic dyslipidemia pattern with combination therapy targeting both LDL-C and triglyceride-rich lipoproteins.